spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec

Oxford Immunotec


 


OXFORD, United Kingdom and MARLBOROUGH, Mass., November 10, 2020 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration between the Company and Public Health England (PHE). The data demonstrates that SARS-CoV-2 reactive T cells may be sufficient to give protection from COVID-19 and that serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection.

 

The paper published on MedRxiv ‘SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers’, presents data generated as part of the EDSAB-HOME study which investigated both antibody (serology) and T cell responses in a cohort of police, fire and healthcare workers.

In the study, T cell tests were conducted at enrolment in almost 3,000 participants using the Company’s standardised research use only T-SPOT®Discovery SARS-CoV-2 assay. These individuals were then followed up for subsequent development of symptomatic, PCR confirmed SARS-CoV-2 infection. None of the participants with a high T cell response developed symptomatic SARS-CoV-2 infection in the follow-up period, whereas amongst those with low T cell responses there were 20 confirmed infections. Further follow-up is planned allowing for updated analyses as case numbers rise which may help yield additional insights into disease risk.

These, and additional results from the data, suggest that:

  • Serology alone may underestimate the working age population at lower risk of clinical SARS-CoV-2 infection
  • Individual level risk stratification may be possible using T cell assays
  • Numbers of individuals with high levels of SARS-CoV-2 responsive T cells declines with increasing age, specifically in the absence of antibodies (serology), and this may explain higher illness incidence and severity in this group
  • The T-SPOT Discovery SARS-CoV-2 test detected PCR confirmed SARS-CoV-2 infections that were not positive in antibody (serology) testing.

Dr. David Wyllie, Consultant Microbiologist at Public Health England and the lead author of the study, said “We conducted a prospective cohort study in almost three thousand volunteers working in hospitals, and in the fire and police services in England. Four months into the study, 20 participants with lower T cell responses had developed COVID-19, compared with none among individuals with higher T cell responses. This suggests individuals with higher numbers of T-cells recognising SARS-CoV-2 may have some level of protection from COVID-19, although more research is required to confirm this.”

Oxford Immunotec CEO, Dr Peter Wrighton-Smith said, “Our T-SPOT technology platform is the only globally regulated ELISPOT platform currently available and we are pleased that we may be able to use it to support efforts to combat COVID-19. Our collaboration with Public Health England is a great example of the public and private sector working together. The successful outcomes of this study would not have been possible without the specialist skills and resource available within Public Health England.”

T-SPOT Discovery SARS-CoV-2 is for research use only, not for use in diagnostic procedures

Not all products are available in all regions, please contact us for information on availability in any specific country

For further information visit: https://www.tspotdiscovery.com

To view the publication visit: https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v1

phone +44 (0) 1235 442 780
email info@oxfordimmunotec.com
web www.oxfordimmunotec.com/international/
email Global Headquarters & UK Oxford Diagnostic Laboratories Oxford Immunotec Global PLC 143 Park Drive Milton Park Abingdon Oxfordshire OX14 4SE
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Faller Packaging offers tailor-made packages for vaccine vials

The search for a vaccine against the novel SARS-CoV-2 coronavirus is currently in full swing – and every day hundreds of thousands of people are vaccinated against other infectious agents. The challenge for the pharmaceutical industry is not only to manufacture vaccines and sera, but also to deliver them securely and undamaged to destinations throughout the world. Faller Packaging offers effective solutions for this purpose.
More info >>


White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement